Phase 1 clinical trials remain vital for oncology care. Patients on these trials require supportive care for quality-of-life (QOL) concerns.
Objective:
To test a Palliative Care Intervention (PCI) for patients with solid tumors enrolled in Phase I therapeutic trials with a priori hypothesis that psychological distress, QOL, satisfaction, symptoms, and resource utilization would be improved in the PCI group.
Design:
This unblinded randomized trial compared the PCI with usual care in patients accrued to Phase I Clinical Trials. Subjects (n = 479) were followed for 24 weeks, with 12 weeks as the primary outcome.
Setting:
Two Comprehensive Cancer Centers in the United States.
Subjects:
A consecutive sample, 21 years or older, English fluency, with solid tumors initiating a Phase 1 trial. Measurements: Psychological Distress (Distress Thermometer), QOL total and subscales (FACT-G), satisfaction (FAM-CARE), survival, and resource utilization (chart audit).
Results:
PCI subjects showed improved Psychological Distress (−0.47, p = 0.015) and Emotional Well-Being (0.81, p = 0.045), with differences on variables of QOL and distress between sites. High rates of symptom-management admissions (41.3%) and low rates of Advance Directive completion (39.0%), and hospice enrollment (30.7%), despite a median survival in both groups of 10.1 months from initiating a Phase 1 study.
Conclusions:
A nurse-delivered PCI can improve some QOL outcomes and distress for patients participating in Phase 1 trials. Greater integration of PC is needed to provide quality care to these patients and to support transitions from treatment to supportive care, especially at the end of life.
ComorettoN, LarumbeA, ArantzamendiM, CentenoC: Palliative care consultants' ethical concerns with advanced cancer patients participating in phase 1 clinical trials: A case study. Prog Palliat Care, 2017; 25:230–234.
2.
GodskesenT, NygrenP, NordinK, et al.: Phase 1 clinical trials in end-stage cancer: Patient understanding of trial premises and motives for participation. Support Care Cancer, 2013; 21:3137–3142.
3.
JenkinsV, Solis-TrapalaI, LangridgeC, et al.: What oncologists believe they said and what patients believe they heard: An analysis of phase I trial discussions. J Clin Oncol, 2011; 29:61–68.
4.
NielsenZE, BerthelsenCB: Cancer patients' perceptions of factors influencing their decisions on participation in clinical drug trials: A qualitative meta-synthesis. J Clin Nurs, 2019; 28:2443–2461.
5.
FultonJJ, LeBlancTW, CutsonTM, et al.: Integrated outpatient palliative care for patients with advanced cancer: A systematic review and meta-analysis. Palliat Med, 2019; 33:123–134.
6.
JangRW, KrzyzanowskaMK, ZimmermannC, et al.: Palliative care and the aggressiveness of end-of-life care in patients with advanced pancreatic cancer. J Natl Cancer Inst, 2015; 107:dju424.
7.
National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for Quality PalliativeCare, 4th ed. RichmondVA: National Coalition for Hospice and PalliativeCare, 2018. www.nationalcoalitionhpc.org/ncp/ (Last accessed September10, 2020).
8.
FinlayE, LuHL, HendersonHR, et al.: Do phase 1 patients have greater needs for palliative care compared with other cancer patients?. Cancer, 2009; 115:446–453.
9.
TemelJS, GreerJA, AdmaneS, et al.: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: Results of a randomized study of early palliative care. J Clin Oncol, 2011; 29:2319–2326.
10.
FerrellBR, TemelJS, TeminS, et al.: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 2017; 35:96–112.
11.
HuiD, ParsonsH, NguyenL, et al.: Timing of palliative care referral and symptom burden in phase 1 cancer patients: A retrospective cohort study. Cancer, 2010; 116:4402–4409.
12.
FerrellBR, PatersonCL, HughesMT, et al.: Characteristics of participants enrolled onto a randomized controlled trial of palliative care for patients on phase I studies. J Palliat Med, 2017; 20:1338–1344.
13.
CutilloA, O'HeaE, PersonS, et al.: The distress thermometer: Cutoff points and clinical use. Oncol Nurs Forum, 2017; 44:329–336.
14.
SunV, CookeL, ChungV, et al.: Feasibility of a palliative care intervention for cancer patients in phase I clinical trials. J Palliat Med, 2014; 17:1365–1368.
15.
AnwarS, TanW, HongC-C, et al.: Quality-of-life (QOL) during screening for phase 1 trial studies in patients with advanced solid tumors and its impact on risk for serious adverse events. Cancers (Basel), 2017; 9:73.
16.
AthertonPJ, SzydloDW, ErlichmanC, SloanJA: What can phase I clinical trials tell us about quality of life? A pilot study (MC0115). Clin Res Trials, 2015; 1:11–14.
17.
EthierJ-L, ParamsothyT, YouJJ, et al.: Perceived barriers to goals of care discussions with patients with advanced cancer and their families in the ambulatory setting: A multicenter survey of oncologists. J Palliat Care, 2018; 33:125–142.
18.
FuS, BarberFD, NaingA, et al.: Advance care planning in patients with cancer referred to a phase I clinical trials program: The MD Anderson Cancer Center experience. J Clin Oncol, 2012; 30:2891–2896.
19.
LeBlancTW: Hope, phase I trials, and palliative care: So you're telling me there's a chance?. J Oncol Pract, 2017; 13:675–677.
20.
JansenLA, MahadevanD, ApplebaumPS, et al.: Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer, 2016; 122:1238–1246.
21.
MillerKD, NogueiraL, MariottoAB, et al.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin, 2019; 69:363–385.
22.
MollicaMA, KentEE, CastroKM, et al.: Perspectives on palliative care in cancer clinical trials: Diverse meanings from multidisciplinary cancer care providers. J Palliat Med, 2018; 21:616–621.
23.
TreasureM, DalyB, FuP, et al.V Relationship between phase I study duration and symptom burden. Support Care Cancer, 2018; 26:731–737.
24.
EnzingerAC, ZhangB, WeeksJC, PrigersonHG: Clinical trial participation as part of end-of-life cancer care: Associations with medical care and quality of life near death. J Pain Symptom Manage, 2014; 47:1078–1090.
25.
FerrellB, SunV, HurriaA, et al.: Interdisciplinary palliative care for patients with lung cancer. J Pain Symptom Manage, 2015; 50:758–767.
LoC, BurmanD, RodinG, et al.: Measuring patient satisfaction in oncology palliative care: Psychometric properties of the FAMCARE-patient scale. Qual Life Res, 2009; 18:747–752.
29.
LoC, BurmanD, HalesS, et al.: The FAMCARE-Patient scale: Measuring satisfaction with care of outpatients with advanced cancer. Eur J Cancer, 2009; 45:3182–3188.
30.
MoorcraftSY, MarriottC, PeckittC, et al.: Patients' willingness to participate in clinical trials and their views on aspects of cancer research: Results of a prospective patient survey. Trials, 2016; 17:17.
31.
CattS, LangridgeC, FallowfieldL, et al.: Reasons given by patients for participating, or not, in phase 1 cancer trials. Eur J Cancer, 2011; 47:1490–1497.
RocqueGB, BarnettAE, IlligLC, et al.: Inpatient hospitalization of oncology patients: Are we missing an opportunity for end-of-life care?. J Oncol Pract, 2013; 9:51–54.
TemelJS, SloanJ, ZemlaT, et al.: Multisite, randomized trial of early integrated palliative and oncology care in patients with advanced lung and gastrointestinal cancer: Alliance A221303. J Palliat Med, 2020; 23:922–929.
36.
AgrawalM, GradyC, FaircloughDL, et al.: Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol, 2006; 24:4479–4484.
37.
GodskesenT, KihlbomU: “I have a lot of pills in my bag, you know”: Institutional norms in the provision of hope in phase I clinical cancer trials. J Oncol Pract, 2017; 13:679–682.
38.
van der BiessenDA, van der HelmPG, KleinD, et al.: Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation. Psychooncology, 2018; 27:163–170.
39.
CoxAC, FallowfieldLJ, JenkinsVA: Communication and informed consent in phase 1 trials: A review of the literature. Support Care Cancer, 2006; 14:303–309.
